sacubitril / valsartan
This is a summary of the European public assessment report (EPAR) for Neparvis. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Neparvis.
For practical information about using Neparvis, patients should read the package leaflet or contact their doctor or pharmacist.
Neparvis : EPAR - Summary for the public (PDF/76.18 KB)
First published: 13/06/2016
Last updated: 13/06/2016
Neparvis : EPAR - Risk-management-plan summary (PDF/90.63 KB)
First published: 07/12/2020
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Novartis Europharm Limited
|Date of issue of marketing authorisation valid throughout the European Union||
11/02/2021 Neparvis - EMEA/H/C/004343 - R/0032
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Agents acting on the renin-angiotensin system
Neparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.